Cargando…

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials

Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving, early detection of relapse-independent progression remains difficult. This is further complicated by superimposed relapses and compensatory mechanisms that allow for silent progression. The term relapsing mult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bayas, Antonios, Christ, Monika, Faissner, Simon, Klehmet, Juliane, Pul, Refik, Skripuletz, Thomas, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880589/ https://www.ncbi.nlm.nih.gov/pubmed/36710720 http://dx.doi.org/10.1177/17562864221146836

Ejemplares similares

Acute hemorrhagic leukoencephalitis (Weston-Hurst syndrome) in a patient with relapse-remitting multiple sclerosis
por: Yildiz, Özlem, et al.
Publicado: (2015)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
por: Möhn, Nora, et al.
Publicado: (2020)

Large-scale cross-sectional online survey on patient-neurologist communication, burden of disease assessment and disease monitoring in people with multiple sclerosis
por: Christ, Monika, et al.
Publicado: (2023)

Teriflunomide for the treatment of relapsing–remitting multiple sclerosis: patient preference and adherence
por: Bayas, Antonios, et al.
Publicado: (2015)

Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
por: Möhn, Nora, et al.
Publicado: (2020)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease
por: Dimitriou, Nikolaos G., et al.
Publicado: (2023)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Clinically Isolated Syndrome According to McDonald 2010: Intrathecal IgG Synthesis Still Predictive for Conversion to Multiple Sclerosis
por: Schwenkenbecher, Philipp, et al.
Publicado: (2017)

Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients
por: Pul, Refik, et al.
Publicado: (2012)

Longitudinal time-domain optic coherence study of retinal nerve fiber layer in IFNβ-treated and untreated multiple sclerosis patients
por: PUL, REFIK, et al.
Publicado: (2016)

The Persisting Significance of Oligoclonal Bands in the Dawning Era of Kappa Free Light Chains for the Diagnosis of Multiple Sclerosis
por: Schwenkenbecher, Philipp, et al.
Publicado: (2018)

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
por: Ingwersen, J., et al.
Publicado: (2023)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Gilles de la Tourette syndrome is not linked to contactin-associated protein receptor 2 antibodies
por: Sühs, Kurt-Wolfram, et al.
Publicado: (2015)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Prolonged-release fampridine for the treatment of myoclonus after cervical myelitis: a case report
por: Müller, Mona Klara Ros, et al.
Publicado: (2022)

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis
por: Wiendl, Heinz, et al.
Publicado: (2015)

Progressive multiple sclerosis: latest therapeutic developments and future directions
por: Faissner, Simon, et al.
Publicado: (2019)

Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies
por: Hernandez, Luis, et al.
Publicado: (2020)

Intrathecal synthesis of anti-Hu antibodies distinguishes patients with paraneoplastic peripheral neuropathy and encephalitis
por: Schwenkenbecher, Philipp, et al.
Publicado: (2016)

The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients
por: Rovituso, Damiano M., et al.
Publicado: (2015)

Autoimmune encephalitis associated with antibodies against the metabotropic glutamate receptor type 1: case report and review of the literature
por: Christ, Monika, et al.
Publicado: (2019)

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination
por: Bayas, Antonios, et al.
Publicado: (2021)

Giant cell arteritis with vertebral artery involvement—baseline characteristics and follow-up of a monocentric patient cohort
por: Prünte, Mona Klara Ros, et al.
Publicado: (2023)

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
por: Sharmin, Sifat, et al.
Publicado: (2023)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

McDonald Criteria 2010 and 2005 Compared: Persistence of High Oligoclonal Band Prevalence Despite Almost Doubled Diagnostic Sensitivity
por: Schwenkenbecher, Philipp, et al.
Publicado: (2016)

Fumaric Acids Do Not Directly Influence Gene Expression of Neuroprotective Factors in Highly Purified Rodent Astrocytes
por: Pars, Kaweh, et al.
Publicado: (2019)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes
por: Ntoskou, Katerina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q0sb4o7qc39iviqqaof4le10vv